GRTS Gritstone Oncology Inc.

Gritstone Oncology Inc. is engaged in the discovery and development of cancer immunotherapies. The company focuses on developing tumor-specific neo-antigens-based therapies for non-small cell lung cancer. Gritstone Oncology Inc. has a strategic collaboration with bluebird bio, Inc. The company was incorporated in 2015 and is based in San Francisco, California with operations in Cambridge, Massachusetts.

$11.60  -0.61 (-5.00%)
As of 12/03/2021 15:59:57 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  09/28/2018
Outstanding shares:  67,987,825
Average volume:  1,458,799
Market cap:   $830,131,343
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    39868T105
ISIN:        US39868T1051
Sedol:      BF12XF5
Valuation   (See tab for details)
PE ratio:   -10.86
PB ratio:   3.58
PS ratio:   17.85
Return on equity:   -34.85%
Net income %:   -155.87%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy